Every Journey Starts With a Step
We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward.
1989
- Salix Pharmaceuticals is founded in Sunnyvale, California
1990
- COLAZAL® (balsalazide disodium) is licensed
1996
- XIFAXAN® (rifaximin) is licensed
2000
- Operations move to Raleigh, North Carolina
- COLAZAL® (balsalazide disodium) receives FDA approval
2004
- XIFAXAN® (rifaximin) 200 mg receives FDA approval
2006
- MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval
2008
- APRISO® (mesalamine granules) receives FDA approval
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for opioid-induced constipation (OIC) in adults with advanced illness when other medicines for constipation have not worked well enough
2009
- OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval
2010
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for hepatic encephalopathy (HE)
2013
- UCERIS® (budesonide) extended-release tablets receives FDA approval
- GIAZO® (mesalamine) receives FDA approval
2014
- Salix acquires Santarus
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for OIC in adults with chronic non-cancer pain
2015
- UCERIS® (budesonide) rectal foam receives FDA approval
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for irritable bowel syndrome with diarrhea (IBS-D)
- Valeant acquires Salix
- Operations begin moving to Bridgewater, New Jersey, our current location
2016
- Salix launches RELISTOR® (methylnaltrexone bromide) tablets
2017
- Salix scales up sales force by nearly 40%